Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 25 versus METHYLTESTOSTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 25 versus METHYLTESTOSTERONE.
ANDROID 25 vs METHYLTESTOSTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Methyltestosterone is a synthetic androgen that binds to and activates androgen receptors (AR) in target tissues, promoting the development and maintenance of male secondary sexual characteristics and anabolic effects. It also suppresses gonadotropin-releasing hormone (GnRH) secretion via negative feedback, reducing endogenous testosterone production.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
10-50 mg orally once daily or divided twice daily, or 10-25 mg buccally twice daily.
None Documented
None Documented
Clinical Note
moderateMethyltestosterone + Digoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethyltestosterone + Digitoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethyltestosterone + Deslanoside
"Methyltestosterone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethyltestosterone + Acetyldigitoxin
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
2-4 hours (terminal); requires multiple daily dosing or transdermal route due to short half-life.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Renal (primarily as glucuronide and sulfate conjugates, ~90%); fecal (~10%). Unchanged drug is minimal.
Category C
Category D/X
Androgen
Androgen
"Methyltestosterone may decrease the cardiotoxic activities of Acetyldigitoxin."